The integration of pharmaceutical investment enterprise channels must not be ignored

In the current situation of the pharmaceutical investment industry, each company has its own channels and regions that cannot be penetrated in the short term. The channels and regions that these a companies consider to be blank are often the advantages of b companies, and they have different resources for different channels. For both parties, through these blank markets and blank channels, the development of advantageous enterprises for cooperative alliances can maximize the potential of the market, enhance the company's sales and brand influence, and it is a win-win situation.

According to the pharmaceutical agent, many different channels appear to be closed on the surface of the terminal market. In fact, they are interconnected and dependent on each other. Can not be separated from the channel integration, the so-called channel integration is to integrate the use of channel resources, the single channel to a complementary multi-channel. Pharmaceutical investment analysis from the perspective of distribution strategy, single-brand distribution of a single channel, from the perspective of resource allocation and utilization, is a waste, from the point of view of the management of pharmaceutical investment enterprises, is not conducive to improving the competitiveness of the competition.

However, some small and medium-sized medicine investment holding companies took the products that had been eliminated, changed the packaging to put a brand, made some investment advertisements, issued several flyers, and began to invite investment across the country, often without a successful model market and without success. The product marketing model, or the model he advocates, cannot be profitable at all, but believes that the product will marry off, regardless of life or death. After operating for a period of time, the dealers discovered that the model was not good, the products were obsolete, and the market did not pay. At this time, the dealers were too late!

The future competition of drug agency companies is not only the competition of products but also the competition of distribution channels. More and more companies have found that it is very difficult to win the market competition simply because of the independent advantages of products, prices, and even advertising homogeneity. Only the differentiation of "channels" and "brands" can create competitive advantages. When new products are listed on the market, they should take into account the complementarity and integration of channels, the mutual benefits of channels, and the conflicts between channels.

Pharmaceutical agents believe that for the existing resident pharmaceutical investment recruiters of pharmaceutical investment enterprises, they should have strong market control capabilities on the one hand. It has high professional knowledge and understands the actual situation of the local market. It can explore the sales channel and strategy of the product based on the changes in the market. At the same time, it should also have good relationship management capabilities. Good at cooperating with peer companies in the local market, etc. to explore and establish their own cooperation opportunities. And for the current pharmaceutical investment industry, this ability has a significant effect on the promotion of investment promotion.